within Pharmacolibrary.Drugs.ATC.N;

model N07XX59
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 20.0,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Dextromethorphan, in combination drug formulations, is a non-opioid antitussive (cough suppressant) commonly used to reduce cough. Combinations can include various agents, such as antidepressants or other CNS-active drugs, and may be used for cough suppression or for research into central nervous system disorders. While dextromethorphan-containing combinations for cough are approved, combinations used for research in conditions like pseudobulbar affect (e.g., with quinidine) may have specific indications.</p><h4>Pharmacokinetics</h4><p>Estimated typical adult values for oral dosing based on known pharmacokinetic properties of dextromethorphan in combination products; no direct published studies report compartmental model parameters specifically for combinations assigned to N07XX59.</p><h4>References</h4><ol><li><p>Hu, Z, et al., &amp; Zhou, S (2005). Herb-drug interactions: a literature review. <i>Drugs</i> 65(9) 1239–1282. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200565090-00005&quot;>10.2165/00003495-200565090-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15916450/&quot;>https://pubmed.ncbi.nlm.nih.gov/15916450</a></p></li><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993656/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Wang, J, et al., &amp; Wang, X (2019). Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. <i>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</i> 27(3) 819–827. DOI:<a href=&quot;https://doi.org/10.1007/s00520-018-4331-x&quot;>10.1007/s00520-018-4331-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30084103/&quot;>https://pubmed.ncbi.nlm.nih.gov/30084103</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX59;
